

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 25, 2011**

**LECTEC CORPORATION**

(Exact name of registrant as specified in its charter)

**Minnesota**

(State or other jurisdiction  
of incorporation)

**0-16159**

(Commission File Number)

**41-1301878**

(IRS Employer Identification No.)

**1407 South Kings Highway,  
Texarkana, Texas**

(Address of principal executive offices)

**75501**

(Zip Code)

Registrant's telephone number, including area code: **(903) 832-0993**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 1.01. Entry Into a Material Definitive Agreement.**

In July 2008, LecTec Corporation (the “*Company*”) filed a complaint for patent infringement against Prince of Peace Enterprises, Inc. (“*POP*”) and four other defendants in the U.S. District Court for the Eastern District of Texas. On April 25, 2011, the Company entered into a Confidential Settlement Agreement and Mutual Release (the “*Settlement Agreement*”) with POP to settle the Company’s claims against POP that POP infringed two of the Company’s patents related to the Company’s medicated patch technology and issued a press release announcing its entry into the Settlement Agreement. A copy of the press release is attached to this Current Report on Form 8—K as Exhibit 99.1, which is incorporated herein by reference.

Pursuant to the Settlement Agreement, POP will pay the Company a one—time sum of \$225,000 and the Company will grant to POP a fully paid—up, world—wide, non—exclusive and irrevocable license to (a) U.S. Patent Nos. 5,536,263 and 5,741,510 (the “*Patents—In—Suit*”), (b) any patent that claims priority, directly or indirectly, from the Patents—In—Suit (the “*Family Patents*”) and (c) any foreign counterparts of the Family Patents, for use in connection with any product or process sold or used by POP, other than products covered by exclusive licenses previously granted to other companies

In addition, under the Settlement Agreement the Company and POP entered into mutual releases of all claims.

The Settlement Agreement will be filed as an exhibit to the Company’s Quarterly Report on Form 10—Q for the quarter ended June 30, 2011.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 LecTec Corporation Press Release, dated April 26, 2011.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LECTEC CORPORATION

By: /s/ Gregory G. Freitag  
Gregory G. Freitag  
Chief Executive Officer and Chief Financial Officer

Date: April 26, 2011

---

## EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	LecTec Corporation Press Release, dated April 26, 2011.

**LecTec Corporation Reports Settlement With Prince of Peace Enterprises.**

April 26, 2011

TEXARKANA, Texas—(BUSINESS WIRE)—LecTec Corporation (OTCBB: LECT) announced today that LecTec has settled its pending patent infringement lawsuit against Prince of Peace Enterprises. Prince of Peace has agreed to make a one-time, \$225,000 payment to LecTec for a non-exclusive license to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510, and any other LecTec patents that claim priority from these two patents, for use in connection with any product or process sold or used by Prince of Peace, other than products covered by exclusive licenses previously granted to other companies. Such settlement proceeds are before paying contingent legal fees and prior to any tax effect.

Greg Freitag, LecTec's CEO stated: "This settlement completes the legal action that LecTec began in 2008. With this chapter closed, the company is squarely focused on putting its cash and public status to work through our merger and acquisition strategy. Remaining LecTec assets other than cash continue to be evaluated as to the ability to provide any additional value to our shareholders. We appreciate the patient support provided by the LecTec shareholders and believe we will be successful as we continue forward with our business plan."

**About LecTec**

LecTec is an intellectual property ("IP") licensing and holding company with approximately \$9 million in cash, cash equivalents, and Federal Deposit Insurance Corporation ("FDIC") insured certificates of deposit at December 31, 2010. LecTec is pursuing a merger and acquisition strategy which is intended to leverage its cash asset and improve shareholder value and liquidity. LecTec holds multiple domestic and international patents based on its original hydrogel patch technology and has filed patent applications on a hand sanitizer patch. LecTec also has a licensing agreement ("Novartis Agreement") with Novartis Consumer Health, Inc., under which LecTec receives royalties from time to time based upon a percentage of Novartis' net sales of licensed products. An effort to monetize LecTec's intellectual property is also ongoing. LecTec's website is [www.lectec.com](http://www.lectec.com).

---

## **Cautionary Statements**

This press release contains forward—looking statements concerning possible or anticipated future results of operations or business developments, which are typically preceded by the words “believes,” “wants,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. Such forward-looking statements are subject to risks and uncertainties which could cause results or developments to differ materially from those indicated in the forward—looking statements. Such risks and uncertainties include, but are not limited to, LecTec’s dependence on royalty payments from Novartis Consumer Health, Inc., which is selling an adult vapor patch licensed from LecTec, LecTec’s dependence on key personnel and Board of Director members, the issuance of new accounting pronouncements, information disseminated on internet message boards from posters expressing opinions that may or may not be factual, the availability of opportunities for license, sale or strategic partner agreements related to patents that LecTec holds, limitations on market expansion opportunities, and other risks and uncertainties detailed from time to time in LecTec’s filings with the Securities and Exchange Commission, and particularly as described in the “Risk Factors” included in our Form 10—K for the year ended December 31, 2010.

## **Contacts**

LecTec Corporation, Greg Freitag, CEO/CFO (903) 832-0993